VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
Valbiotis has been listed on Euronext Growth since 7 June 2017.
Analyst: Christophe Dombu
Analyst: Thibaut Voglimacci-Stephanopoli